Table 2.
Relationship between IPM-defined risk and patient characteristics at diagnosis in Stage I-II LUAD patients in the TCGA cohort.
| Variable | All | IPM defined risk | P value | |
|---|---|---|---|---|
| IPM-LR | IPM-HR | |||
| Number of patients | 164 | 114 | 50 | |
| Age (year, median, range) | 67 (41–86) | 68 (41–86) | 65.5 (42–85) | <0.0001 |
| Males (%) | 69 (42.1%) | 46 (40.4%) | 23 (46%) | 0.61 |
| Smoker, n (%) | ||||
| Smokers | 133 (81.1%) | 93 (81.6%) | 40 (80.0%) | 0.63 |
| Never smokers | 25 (15.2%) | 16 (14.0%) | 9 (18.0%) | |
| Not Available | 6 (3.7%) | 5 (4.4%) | 1 (2.0%) | |
| Survival status, n (%) | ||||
| alive | 106 (64.6%) | 85 (74.6%) | 21 (42%) | <0.0001 |
| dead | 58 (35.4%) | 29 (25.4%) | 29 (58%) | |
| T stage, n (%) | ||||
| T1 | 58 (35.4%) | 45 (39.5%) | 13 (26%) | 0.11 |
| T2-3 | 106 (64.6%) | 69 (60.5%) | 37 (74%) | |
| N stage, n (%) | ||||
| N0 | 124 (75.6%) | 89 (78.1%) | 11 (55.0%) | <0.0001 |
| N1 | 35 (21.3%) | 20 (17.5%) | 15 (35.0%) | |
| Nx | 5 (3%) | 5 (4.4) | 0 (0%) | |
| Residual tumor, n (%) | ||||
| R0 | 116 (70.7%) | 83 (72.8%) | 33 (66.0%) | 0.84 |
| R1 | 5 (3.0%) | 3 (2.6%) | 2 (4.0%) | |
| Rx | 3 (1.8%) | 2 (1.8%) | 1 (2.0%) | |
| Not Available | 40 (24.4%) | 26 (22.8%) | 14 (28.0%) | |
| EGFR, n (%) | ||||
| Mutation | 25 (15.2%) | 16 (14.0%) | 9 (18.0%) | 0.64 |
| Wild type | 139 (84.8%) | 98 (86.0%) | 41 (82.0%) | |
| ALK, n (%) | ||||
| Mutation | 15 (9.1%) | 10 (8.8%) | 5 (10.0%) | 0.78 |
| Wild type | 149 (90.9%) | 104 (91.2%) | 45 (90.0%) | |
| ROS1, n (%) | ||||
| Mutation | 10 (6.1%) | 7 (6.1%) | 3 (6.0%) | 0.97 |
| Wild type | 154 (93.1%) | 107 (93.9%) | 47 (94.0%) | |
| BRAF, n (%) | ||||
| Mutation | 15 (9.1%) | 10 (8.8%) | 5 (10.0%) | 0.80 |
| Wild type | 149 (90.9%) | 104 (91.2%) | 45 (90.0%) | |
| WT/MUT Group, n (%) | ||||
| MUT group | 58 (35.4%) | 38 (33.3%) | 20 (40.0%) | 0.41 |
| WT group | 106 (64.6%) | 76 (66.7%) | 30 (60.0%) | |